Kopion Asset Management LLC Boosts Stock Holdings in Certara, Inc. $CERT

Kopion Asset Management LLC boosted its holdings in Certara, Inc. (NASDAQ:CERT) by 49.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 982,710 shares of the company’s stock after acquiring an additional 327,064 shares during the period. Certara comprises about 6.2% of Kopion Asset Management LLC’s investment portfolio, making the stock its 8th biggest holding. Kopion Asset Management LLC’s holdings in Certara were worth $8,658,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in CERT. First Horizon Corp bought a new stake in shares of Certara in the 3rd quarter worth approximately $30,000. Versant Capital Management Inc grew its stake in Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after buying an additional 1,153 shares during the last quarter. Osaic Holdings Inc. grew its stake in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in Certara in the second quarter worth $59,000. Finally, Global Retirement Partners LLC lifted its stake in Certara by 45.0% in the third quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock valued at $69,000 after buying an additional 1,749 shares during the last quarter. 73.96% of the stock is owned by institutional investors.

Certara Stock Performance

CERT opened at $6.38 on Friday. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27. The firm has a market cap of $1.02 billion, a PE ratio of -638.00 and a beta of 1.50. The business has a fifty day simple moving average of $7.74 and a 200-day simple moving average of $9.49. Certara, Inc. has a fifty-two week low of $6.04 and a fifty-two week high of $15.38.

Certara (NASDAQ:CERT) last announced its earnings results on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The firm had revenue of $103.65 million during the quarter, compared to analyst estimates of $103.23 million. During the same quarter in the previous year, the business earned $0.15 earnings per share. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Barclays reiterated an “equal weight” rating and issued a $8.00 price objective on shares of Certara in a research report on Friday, March 6th. Craig Hallum lowered shares of Certara from a “buy” rating to a “hold” rating and set a $10.00 price target on the stock. in a research note on Friday, February 27th. Leerink Partners reaffirmed an “outperform” rating and set a $10.00 price target on shares of Certara in a report on Thursday, February 26th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Finally, KeyCorp decreased their price objective on Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Certara presently has a consensus rating of “Hold” and an average price target of $11.10.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.